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Introduction
A still and bloodless operative field provides the surgeon with optimal 
conditions to perform delicate coronary anastomosis, while effective 
myocardial protection avoids myocardial injury during this process.1 
Cold crystalloid cardioplegia has been the cornerstone of this strategy 
by inducing electromechanical arrest and further reducing oxygen 
demand with hypothermia.2 In spite of demonstrable improvements 
attributed to blood-based hyperkalaemic solutions,3,4  including 
superior preservation of myocardial and  coronary endothelial 
function, 5,6 especially in the setting of a dysfunctional or ischaemic 
myocardium,7-9 crystalloid solutions remain in widespread use. The 
technique of warm substrate-enhanced sanguineous reperfusion, 
delivered under controlled flow and pressure, is recognized as a 
valuable adjunct to blood-based cardioplegia, but is not part of the 
crystalloid protocol.  Popularly known as the ‘hot shot’, it provides 
endogenous oxygen free radical scavengers and prevents myocardial 
substrate derangement.10,11 However, simple normokalaemic 
blood reperfusion, under certain conditions, and without substrate 
enhancement, may still attenuate reperfusion injury by providing 
acid-base homeostasis via the bicarbonate buffering system.12 The 
method of its administration may partly reproduce the controlled 
pressure and flow conditions in the hot shot, by limiting the initial 
blood flow during early reperfusion. 
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Abstract
Background: Cold crystalloid cardioplegic arrest remains a well recognised method of myocardial protection. This strategy does not 
allow for a controlled hyperkalaemic sanguineous reperfusate, known as a “hot shot” which is administered under constant flow and 
pressure conditions in order to limit reperfusion injury. We investigated the use of intermittent, antegrade cold crystalloid cardioplegia 
(St Thomas’ I solution) combined with a limited flow normokalaemic sanguineous reperfusion and measured the outcome in terms of 
the incidence of reperfusion ventricular fibrillation.
Methods: Patients requiring coronary revascularization of at least two coronary arteries, including an internal thoracic artery (ITA) 
anastomosis, were studied in this prospective randomized trial. Myocardial protection was by intermittent, antegrade cold crystalloid 
cardioplegia. In the control group (n=100), after completion of the distal anastomoses, the heart was reperfused by releasing the aortic 
and ITA clamps concomitantly. In the study group (n=100) the ITA was allowed to perfuse the heart for 3 minutes before the aortic 
cross-clamp was removed. The presence of reperfusion ventricular fibrillation from the moment of reperfusion until weaning from 
cardiopulmonary bypass was recorded.
Results: Mean ischaemic times varied marginally between the study and control groups (study 35.60±8.65, control 35.79±10.64, 
p=0.89). The incidence of ventricular fibrillation decreased with an increase in the number of grafts and was significantly lower in the 
study group (double grafts 2/9, 22.2% vs 19/25, 76.0% p=0.004; triple grafts 2/39, 4.9% vs 16/33, 48.5% p<0.001; and quadruple 
grafts 2/45, 4.4% vs 13/35, 28.7% p<0.001). 
Conclusions: This strategy of myocardial protection combines the advantages of conventional crystalloid cardioplegia with the 
added benefit of limited sanguineous reperfusion. It is cost-effective and simple to apply. The results suggest a beneficial effect with 
regard to reperfusion-induced injury, as evidenced by a significantly reduced incidence of reperfusion ventricular fibrillation.
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The occurrence of early ventricular fibrillation (VF) after cross-clamp 
removal is a manifestation of reperfusion injury,13 the consequences 
of which also include myocardial stunning,14 microvascular 
obstruction15 and myocardial necrosis.16  Reperfusion-induced 
arrhythmias are reduced by cardioplegic protection during ischaemia 
and their occurrence bears an inverse relationship to ischaemic 
time.17 The prevention of VF by pharmacologic means has been 
attempted with a view to reducing subsequent myocardial damage.18 
In this study we retained the protocol of antegrade intermittent 
cold crystalloid cardioplegic arrest and combined this with limited 
sanguineous normokalaemic reperfusion, initially allowing flow 
only via the ITA, before establishing full reperfusion by cross-clamp 
removal. We measured the occurrence of early VF as a marker of 
reperfusion injury and investigated this method of reperfusion as a 
possible means of attenuating this injury.
Methods
Patients requiring coronary revascularization of two or more 
coronary arteries, including at least one internal thoracic artery (ITA) 
anastomosis, were randomized to a control or study group in this 
prospective trial. Patients requiring routine or urgent (performed during 
the same week as referral) surgery were recruited whereas patients 
requiring emergency surgery were excluded. Informed consent was 
obtained from each patient and the study protocol conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki as reflected in a 
priory approval by our institution’s human research committee.
Normothermic cardiopulmonary bypass was employed. After 
application of the aortic cross-clamp, cold crystalloid cardioplegia (St 
Thomas’ I solution) was administered into the aortic root as an initial 
dose of 500ml, and continued when necessary if complete cardiac 
standstill and uniform cooling was not attained (figure 1). 
This initial dose was followed by additional 100ml doses after 
each distal anastomosis. This additional dose was omitted before 
the last (ITA) anastomosis to the left anterior descending artery 
(LAD). No topical cooling of the heart was employed. Patients were 
prospectively randomized into a control or study group. In the control 
group (n=100) the aortic cross-clamp was removed concomitantly 
with ITA reperfusion. In the study group (n=100) the ITA was allowed 
to perfuse the heart for 3 minutes before the aortic cross-clamp 
was removed (figure 2). Cardiopulmonary blood flow was transiently 
reduced during cross-clamp removal. Manipulation of the heart was 
avoided during the 3 minute ITA reperfusion period in the study group 
and during the 3 minutes after cross-clamp removal in the control 
group. The occurrence of VF was recorded from the moment of 
reperfusion, by whichever method, until the weaning of the patient 
from cardiopulmonary bypass.
Statistical Methods
Means and standard deviations were used to measure central 
tendency and dispersion for continuous variables and frequency 
tables and crosstabs were used to describe categorical variables. The 
Independent samples t-test was used to compare mean ages and 
mean ischaemic times between the study and control groups given 
that both variables satisfied the normality assumption. The Mann 
Whitney test was used to compare the initial dose of cardioplegia 
in the two groups, which did not satisfy a normal distribution. The 
chi square test was used to compare the incidence of ventricular 
fibrillation in the study and control groups for different number of 
grafts. In both tests a 0.05 level of significance was adopted. 
Results
Age (study 58.8±8.8, control 57.2±9.2, p=0.21), gender distribution 
(study 15% female, control 8% female, p=0.12) initial cardioplegia 
dose (study 584.5±143.5ml, control 590.2±133.6ml, p=0.856), and 
overall ischaemic times were similar in both groups (study 35.60±8.65, 
control 35.79±10.64, p=0.89). Study and control characteristics are 
presented in table 1. The distribution of grafts per case and their 
respective ischaemic times are shown in figure 3.
Figure 1. Initial dose of cardioplegia Figure 2. Protocol for myocardial protection
Table 1. Patient characteristics
study control p value
age 58.8±8.8 57.2±9.2 0.21
female 15 8 0.12
ischaemic time* 35.60±8.65 35.77±10.64 0.89
ejection fraction** 63.57±13.65 60.76±14.36 0.16
urgent surgery 31 24 0.36
EuroSCORE 4.96±1.56 4.99±1.99 0.91
*   mean ischaemic time for entire groups
** ejection fraction measured by ventriculography
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In the absence of VF, both control and study patients exhibited 
complete electrical quiescence or infrequent contractions during 
the 3 minutes of reperfusion.  The incidence of ventricular fibrillation 
decreased with an increase in the number of grafts, down to a 
baseline of around 28% in the control group, and was significantly 
reduced in the study group for double (2/9, 22.2% vs 19/25, 76.0% 
p=0.004), triple (2/39, 4.9% vs 16/33, 48.5% p<0.001) and quadruple 
grafts (2/45, 4.4% vs 13/35, 28.7% p<0.001). VF did not occur with 
quintuple grafts in the study group, while it occurred in 2/7 patients 
(28.6%) in the control group (figure 4).
Discussion
Although the separate manifestations of ischaemia-reperfusion injury 
are expressed to varying degrees depending on the length of ischaemia, 
it is generally accepted that their expression is quantitatively related 
to the magnitude of the ischaemic insult. Thus, infarct size19 and 
global ventricular dysfunction20 although attenuated by cardioplegic 
protection, bear a direct relationship to ischaemic duration. The 
incidence of reperfusion VF has been shown, in a blood-perfused 
animal model, to exhibit an inverse relationship with ischaemic time, 
even after crystalloid cardioplegia administration.17 This relationship 
is also manifest in the clinical setting of this study of global ischaemia 
and reperfusion during coronary surgery. The attenuation of 
reperfusion arrhythmias can therefore be interpreted as a surrogate of 
other deleterious effects of ischaemia-reperfusion. 
Diverse strategies have been investigated with the aim of reducing 
reperfusion injury, especially in the percutaneous coronary intervention 
setting.21-24 The hot shot was popularized to provide such a 
protection in the surgical setting of global ischaemia. Our method of 
reperfusion differs from the hot shot not only in its composition, but 
also in its limited distribution, with reperfusion initially confined to the 
LAD territory. In spite of these fundamental differences this method of 
reperfusion significantly reduced the incidence of VF.
For the many surgeons who still employ crystalloid cardioplegia, we 
describe a simple modification of reperfusion, which significantly 
reduces reperfusion VF, a marker of other, more serious manifestations 
of the ischaemia-reperfusion injury. This method is simple to apply, does 
not significantly lengthen the surgery, incurs no additional equipment 
or cost, and significantly reduces the incidence of reperfusion VF 
thereby reducing the necessity for topical defibrillation.25 
Limitations
The study is relatively small and confined to a single surgeon practice. 
Patients who required emergency surgery were excluded and it is 
possible that in such cases this method of reperfusion may have 
been more beneficial. Other parameters of reperfusion injury, such as 
markers of myocardial damage, were not investigated in this study. 
Conclusion
In conclusion we describe a method of limited sanguineous 
normokalaemic reperfusion via the internal thoracic artery, in the 
setting of coronary revascularisation using intermittent cold crystalloid 
cardioplegia. This simple, no-cost protocol significantly diminished 
the incidence the incidence of ventricular fibrillation, a marker of 
reperfusion-induced injury, and should improve myocardial protection 
and efficacy of the cold crystalloid cardioplegia technique.
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